3200威尼斯vip(中国)有限公司

News
NEWS
Home News Industry News
Besides COVID-19 nucleic acid testing, what else can a PCR laboratory do?
2022-10-14

A PCR laboratory is also called a gene amplification laboratory. Real-time fluorescent quantitative PCR technology is a leap forward in DNA quantification technology. It is used to amplify specific DNA fragments and can be regarded as a special form of DNA replication outside an organism.

Through the DNA gene tracking system, the viral load in a patient's body can be quickly determined, with accuracy as high as the nanometer level. Real-time fluorescent quantitative PCR is the vehicle for achieving this technology.PCR experiments are often used to test for viral infectious diseases such as AIDS, hepatitis B, and avian epidemic diseases.By amplifying the genes contained in the virus, it can detect whether infected individuals with low viral loads carry a specific virus.PCR detection methods have advantages such as high sensitivity, high specificity, speed, and low sample requirements, so they are widely recognized by clinicians and have been widely used in clinical diagnosis in hospitals and in the diagnosis of avian epidemic diseases in various epidemic prevention and testing departments.

Driven by national policies and the development of the epidemic, hospitals at all levels in various regions have begun or are preparing to establish independent and compliant PCR laboratories, and medical institutions have already acquired nucleic acid testing capabilities. However, due to differences in the epidemic situation across regions, some nucleic acid laboratories in long-term low-risk areas are almost at a standstill apart from their emergency functions. This situation is also the issue that hospital leaders at all levels worry about most when establishing laboratories: funds and effort have been invested, but they cannot bring revenue to the hospital.


PCR laboratories are actually extremely powerful, and qualitative analysis and quantitative detection are their two largest application directions. So, besides COVID-19 nucleic acid testing, what else can our "all-purpose" PCR laboratory do? Next, we will show several project examples in specific application directions, and we hope that through these examples we can provide some ideas and directions for project development to medical systems at all levels.


(I) Pathogen detection

The advent of PCR technology has enabled pathogen detection to be carried out quickly and conveniently. Because the false-positive rate of PCR technology is too high, a positive result can be obtained as long as a trace amount of pathogen is present, which cannot serve as a diagnostic basis; only when a certain number of pathogens are present does it have clinical significance. Therefore, accurate quantification of the template is particularly important, and the application of fluorescent PCR technology can provide results quickly and accurately. For solving the "window period" problem of immunological testing, determining whether a disease is in a latent or subclinical state, and when antibody testing cannot determine whether it is a current infection or a past infection, PCR can be used for confirmation.

Example:Novel coronavirus nucleic acid testing.

Methodology:Fluorescent PCR method.

Purpose:Used for in vitro qualitative detection of suspected cases of novel coronavirus-infected pneumonia, patients with suspected clustered cases, and others who need diagnosis or differential diagnosis of novel coronavirus infection.

Genes detected: ORF1ab and N gene, E gene of novel coronavirus (2019-nCoV).

Specimen types:Upper respiratory tract specimens: throat swabs, nasal swabs; lower respiratory tract specimens: respiratory tract aspirates, bronchoalveolar lavage fluid samples, lung tissue biopsy specimens.

Testing process:

(1) Biosafety protection before nucleic acid testing (wearing level-3 personal protection for staff) → (2) Inactivation of samples (inactivation at 56°C for 30 minutes) → (3) Nucleic acid extraction of samples (manual, nucleic acid extractor) → (4) Preparation of the PCR system and template loading → (5) Instrument testing and result analysis → (6) Disinfection after testing.

Other pathogen detection:HIV, hepatitis A, B, and C, HPV, Mycoplasma pneumoniae, Chlamydia pneumoniae, EB virus, adenovirus, cytomegalovirus, influenza A and B, Ebola virus, group B Streptococcus.

Hospitals and departments suitable for carrying out this testing:Children's hospitals, maternal and child health hospitals, pediatric inspection institutes, third-party laboratories, and hospitals of various levels with demand.


(II) Genetic disease testing

Gene mutations and copy number variations are the main genetic basis for the occurrence of genetic diseases and are also the main targets of genetic disease testing. The complexity of genetic diseases is accompanied by a large number and wide variety of gene mutations; gene copy number variations are manifested not only as deletions and duplications, but deletion positions, sizes, and duplication multiples also show diversity. The complexity of genetic variation poses technical challenges for the clinical testing of genetic diseases. Real-time PCR technology is a new-generation real-time PCR technology that we have recently developed; by using fluorescent labeling or melting point analysis, it can detect multiple targets in a single reaction tube.

Example:Detection of microdeletions in the AZF region of the human Y chromosome.

Methodology:Fluorescent PCR method.

Purpose:This product is used for qualitative detection of whether there is a deletion in the azoospermia factor (AZF) region of the Y chromosome in male whole blood samples. Specifically,the deletion sites detected are:AZFa: sY84, sY86; AZFb: sY127, sY134; AZFc: sY254, sY255; AZFd: sY145, sY152.

Clinical studies have shown that varying degrees of deletion in the AZF regions of the Y chromosome (AZFa, AZFb, AZFc, AZFd) can lead to oligozoospermia, azoospermia, or sperm abnormalities in men, thereby causing male infertility. This kit can assist in the etiological analysis and definitive diagnosis of infertile patients. The test results are for clinical reference only and cannot be used alone as a basis for clinical diagnosis such as confirming or excluding cases.

Specimen types:Whole blood.

Testing process:

(1) Sample processing and DNA extraction (completed in the specimen preparation area) → (2) Sample processing and DNA extraction (completed in the specimen preparation area) → (3) Sample loading (completed in the specimen preparation area) → (4) PCR amplification (completed in the amplification area) → (5) Result analysis and interpretation.

Other similar items:Thalassemia, deafness, phenylketonuria (PKU), favism (G6PD), spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), ankylosing spondylitis (HLA), hemophilia.

Hospitals and departments suitable for carrying out this testing:Maternal and child health institutions, third-party laboratories, and hospitals of various levels with such needs.


(III) Personalized medication

The development of pharmacology and pharmacogenomics has elucidated the genetic basis of individual differences in drug metabolism and effects. Abnormal drug reactions are mainly caused by genetic variants in drug-metabolizing enzymes that lead to abnormal enzyme activity, which in turn results in drugs not being properly metabolized and eliminated from the body after administration, causing drug concentrations in the body to be too high or too low, failing to achieve the ideal therapeutic effect. Such abnormal drug reactions can be addressed by testing the genes related to the drugs taken by the patient, adjusting drug dosage, or finding alternative drugs, so as to formulate the most reasonable, effective, and economical drug treatment plan to the greatest extent possible.

Example:Cardiovascular personalized medication guidance testing: CYP2C19 gene mutation detection kit, CYP2C9 gene mutation detection kit, ALDH2 gene mutation detection kit, MTHFR gene mutation detection kit.

Methodology:Fluorescent PCR method.

Purpose:Clopidogrel, warfarin, nitroglycerin, and folic acid are all commonly used drugs in cardiovascular clinical practice. Molecular biology testing for cardiovascular medication guidance clarifies the genotype. Clinical pharmacists in the pharmacy department, based on the test results and comprehensively considering the patient's own factors, clinical diagnosis, and concomitant medication and other relevant information, provide personalized medication recommendations for clinical use.

Specimen types:Whole blood (this kit does not require DNA extraction; direct PCR with sample loading).

Testing process:

(1) Prepare the reaction system (completed in the sample preparation area) → (2) Directly add whole blood (completed in the specimen preparation area) → (3) PCR amplification (completed in the amplification area) → (4) Result analysis and interpretation.

Other similar items:Statin medication (ApoE), β-blockers (ADRB1), pediatric safe medication, tumor-targeted chemotherapy personalized medication (EGFR, kRAS), etc.

Hospitals and departments suitable for carrying out this testing:Cardiovascular hospitals, cancer hospitals, third-party laboratories, and hospitals of various levels with such needs.


(IV) Tumor research

Tumor is a disease that endangers human health. Its degree of malignancy and prognosis are mainly determined by whether there is metastasis and pathological staging. With the rapid development of molecular biology, a large number of research findings in the field of tumor research have shown that the occurrence, development, treatment, and prognosis of tumors are related to the genes inside tumor cells and tumor-associated viruses. The detection of the expression of many proto-oncogenes and tumor suppressor genes can reveal the possibility of carcinogenesis, and PCR methodology can address such issues. In addition, PCR methods are used for in vitro qualitative detection of septin9 gene methylation in human peripheral blood plasma for clinical auxiliary diagnosis of various tumors.

Specimen types:Whole blood/tissue.

Testing process:

(1) PCR reaction system construction (completed in the reagent preparation area) (2) Sample processing and DNA extraction (completed in the specimen preparation area) → (3) Bisulfite conversion (completed in the specimen preparation area) → (4) PCR amplification (completed in the amplification area) → (5) Result analysis and interpretation.

Other similar items:SHOX2 gene, RASSF1A gene, SDC2 gene methylation, MGMT gene methylation, RNF180, her2.

Hospitals and departments suitable for carrying out this testing:Cancer hospitals, third-party laboratories, and hospitals of various levels with such needs.


Disclaimer

The images and information in this WeChat post are sourced from Laboratory Medicine, the official website of the National Health Commission, Personal Library, and IVD Study Notes. The purpose is to share better content with more people, and the copyright remains with the original authors.

If there is any infringement involved, please inform us, and we will delete the relevant content within 24 hours. Thank you!

Share to:
Products
Cell Biology
Molecular Biology
Liquid Handling
Bioprocessing
Custom Products
Solutions
Biopharmaceuticals
Cell & Gene Therapy
Vaccines
Diagnostics & Testing
About Us
Company Profile
Corporate Culture
Development History
Honors & Qualifications
Contact Us
Service Hotline: 400-800-6815
Email: info@cellprobio.net
Address: Building 40, No. 18 Dongchang Road, Suzhou Industrial Park
[WeChat Account QR Code]
Copyright © 2023 Suzhou CellPro Biotechnology Co., Ltd. All rights reserved. Record No.:Su ICP No. 19059453-1
Baidu
sogou